IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia (atrasentan) over 2.5 years – Novartis
Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia (atrasentan) versus placebo in adults with IgA nephropathy (IgAN). Results were published in The… read more.
